Menu
March 23, 2021
October 26, 2020
Positive Biomarker Efficacy Results from the ACTION-Galactosemia Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Post-Natal Galactitol Reduction is Associated with Normalization of CNS Phenotype in Animal Model of Galactosemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
American Society of Human Genetics (ASHG) 2020 Annual Meeting
September 23, 2020
AT-001: A Next Generation Aldose Reductase Inhibitor with Improved Potency, Selectivity and Specificity Protects from Cellular Damage Associated with Hyperglycaemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Addressing Safety and Specificity with Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
56th Annual Meeting of the European Association for the Study of Diabetes (EASD)
July 17-19, 2020
AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
December 5-7, 2019
The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD
December 4-7, 2019
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (presentation)
November 16-18, 2019
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study(Please view in Slideshow to hear presentation)
American Heart Association (AHA) Scientific Session 2019
Philadelphia, Pennsylvania
American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas
September 16-20, 2019
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain
September 13-16, 2019
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA
June 7-11, 2019
American Diabetes Association 79th Scientific Sessions
San Francisco, CA
May 25-28, 2019
European Society for Cardiology 6th World Congress on Acute Heart Failure
Athens, Greece
October 15-16, 2018
A Novel Investigational Treatment In Preclinical Development For Galactosemia
NORD Rare Summit 2018
Washington, D.C.
©2020 Applied Therapeutics All Rights Reserved
©2020 Applied Therapeutics All Rights Reserved